RefleXion Medical makes the first PET-guided radiotherapy system, which uses the tumour's own emissions to steer the beam.
RefleXion Medical, based in Hayward, California, makes the first PET-guided radiotherapy system, which uses the tumour's own positron emissions to steer the treatment beam. Its SCINTIX biology-guided radiotherapy received FDA authorisation in 2023 for lung and bone metastases. OnCo links it to MR-guided adaptive radiotherapy and PET as technologies, to the molecular imaging roadmap from FDG through PSMA and FAP to immune PET, to the bottleneck that surgery and radiotherapy cure most patients but get least funding, and to the idea of coverage-with-evidence registries for adaptive radiotherapy. Whether tracking tumours by their own signal allows safe treatment of many metastases at once is the open question the system was built to test. The radiotherapy technology pages carry the evidence.
Shares Linac, proton system and brachytherapy machine manufacturing, Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH.
Shares Linac, proton system and brachytherapy machine manufacturing, Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH.
Shares Coverage-with-evidence registries for MR-guided and adaptive radiotherapy, MR-guided adaptive radiotherapy, Surgery and radiotherapy cure most, get least.
Shares Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH, Surgery and radiotherapy cure most, get least.
Shares Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH, Surgery and radiotherapy cure most, get least.
Shares Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH, Surgery and radiotherapy cure most, get least.
Shares Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH, Surgery and radiotherapy cure most, get least.
Shares Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET, PET (positron emission tomography).